GIACOMELLI, ROBERTO
 Distribuzione geografica
Continente #
AS - Asia 15.454
NA - Nord America 9.641
EU - Europa 3.982
SA - Sud America 1.826
AF - Africa 222
Continente sconosciuto - Info sul continente non disponibili 166
OC - Oceania 55
AN - Antartide 1
Totale 31.347
Nazione #
US - Stati Uniti d'America 9.221
SG - Singapore 8.494
CN - Cina 2.715
HK - Hong Kong 2.223
IT - Italia 1.850
BR - Brasile 1.361
VN - Vietnam 769
GB - Regno Unito 650
FR - Francia 542
BD - Bangladesh 415
DE - Germania 261
IN - India 223
CA - Canada 222
AR - Argentina 182
ID - Indonesia 121
NL - Olanda 120
MX - Messico 102
EC - Ecuador 85
ZA - Sudafrica 80
TR - Turchia 78
UA - Ucraina 74
JP - Giappone 73
CO - Colombia 64
ES - Italia 61
IQ - Iraq 57
RU - Federazione Russa 53
AU - Australia 50
PL - Polonia 45
CL - Cile 39
FI - Finlandia 38
PY - Paraguay 36
SA - Arabia Saudita 34
CZ - Repubblica Ceca 33
MA - Marocco 32
AT - Austria 31
SE - Svezia 29
PE - Perù 26
PK - Pakistan 26
JM - Giamaica 25
EG - Egitto 23
MD - Moldavia 22
PT - Portogallo 22
TN - Tunisia 22
PH - Filippine 21
VE - Venezuela 21
RO - Romania 20
UZ - Uzbekistan 20
CR - Costa Rica 17
IL - Israele 14
JO - Giordania 14
KZ - Kazakistan 14
NP - Nepal 14
KE - Kenya 13
LT - Lituania 13
IR - Iran 12
OM - Oman 12
DK - Danimarca 11
AE - Emirati Arabi Uniti 10
AL - Albania 10
BG - Bulgaria 10
HN - Honduras 10
IE - Irlanda 10
LB - Libano 10
DZ - Algeria 9
GT - Guatemala 9
TH - Thailandia 9
AZ - Azerbaigian 8
CH - Svizzera 8
DO - Repubblica Dominicana 8
ET - Etiopia 8
KR - Corea 8
MY - Malesia 8
BE - Belgio 7
GR - Grecia 7
SK - Slovacchia (Repubblica Slovacca) 7
SV - El Salvador 7
UY - Uruguay 7
EE - Estonia 6
KW - Kuwait 6
RS - Serbia 6
BA - Bosnia-Erzegovina 5
GH - Ghana 5
HU - Ungheria 5
LU - Lussemburgo 5
LV - Lettonia 5
NI - Nicaragua 5
SN - Senegal 5
BO - Bolivia 4
CG - Congo 4
PA - Panama 4
SI - Slovenia 4
TW - Taiwan 4
AF - Afghanistan, Repubblica islamica di 3
BH - Bahrain 3
CY - Cipro 3
IS - Islanda 3
KG - Kirghizistan 3
LK - Sri Lanka 3
PS - Palestinian Territory 3
QA - Qatar 3
Totale 31.112
Città #
San Jose 2.942
Hong Kong 2.198
Ashburn 1.899
Singapore 1.717
Rome 1.287
Hefei 1.104
Council Bluffs 789
Boardman 618
Columbus 575
London 527
Beijing 487
Lauterbourg 473
Shanghai 359
Dallas 347
Ho Chi Minh City 296
New York 162
Santa Clara 155
Hanoi 150
Los Angeles 138
São Paulo 113
Pune 97
San Francisco 94
Amsterdam 78
Toronto 72
Munich 61
Washington 55
Seattle 52
Tokyo 52
Mexico City 47
Naples 44
Milan 42
Brooklyn 37
Haiphong 37
Warsaw 37
Frankfurt am Main 36
Montreal 36
Phoenix 36
Brasília 34
Da Nang 34
Rio de Janeiro 34
Las Vegas 33
Chicago 32
Baghdad 31
Buffalo 31
Ankara 29
Guayaquil 28
Johannesburg 28
Atlanta 25
Quito 25
Stockholm 24
Turku 23
Bari 22
Biên Hòa 22
Guangzhou 22
Nuremberg 21
Porto Alegre 21
Curitiba 20
Thái Bình 20
West Jordan 20
Boston 19
Brno 19
Chennai 19
Buenos Aires 18
Cape Town 18
Hải Dương 18
Jinan 18
Manchester 18
Belo Horizonte 17
Campinas 17
Sydney 17
Vienna 17
Guarulhos 16
Hangzhou 16
Kingston 16
Lima 16
Tashkent 16
Charlotte 15
Jakarta 15
San José 15
Changsha 14
Medellín 14
Riyadh 14
Turin 14
Can Tho 13
Dhaka 13
Helsinki 13
Madrid 13
Manaus 13
Melbourne 13
Amman 12
Bogotá 12
Florence 12
Hortolândia 12
Lấp Vò 12
Ottawa 12
Paris 12
Salvador 12
Tunis 12
Bengaluru 11
Bologna 11
Totale 18.432
Nome #
Fibroblast expression of CD248 may contribute to exacerbate microvascular damage during systemic sclerosis 273
------- 244
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 238
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 236
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 223
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 223
A comprehensive review on adult onset Still's disease 218
AB0550 PHENOTYPE OF BIOPSY-PROVEN PATIENTS WITH PRIMARY SJÖGREN SYNDROME LACKING RO AUTOANTIBODIES: HIGH FREQUENCY OF DRYNESS SYMPTOMS WITH LOW SYSTEMIC ACTIVITY (BIG DATA SJÖGREN PROJECT) 210
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis 209
Cardiometabolic multimorbidity may identify a more severe subset of rheumatoid arthritis, results from a “real-life” study 207
Adipose stromal vascular fraction and regenerative therapy in SSc: Response to the article by Magalon et al 203
Cytokine profile, ferritin, and multi-visceral involvement characterise macrophage activation syndrome during adult-onset Still's disease 198
Clinical characteristics of obese patients with adult-onset Still's disease. Data from a large multicentre cohort 197
Aberrant expression of IL-22RA1 on hematopoietic cells as immunologically signature of primary sjogren’s syndrome and sjogren-associated non-hodgkin lymphomas 196
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 194
AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME (PSS) 193
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups 185
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 180
Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry 177
A3.1 Pathogenic role of IL-17 producing double negative (DN) T cells in primary sjögren’s syndrome 176
Bosentan effect on echocardiographic systolic pulmonary arterial pressure in systemic sclerosis-related pulmonary hypertension: a systematic review and metanalysis 172
Adult-onset Still's disease with elderly onset: results from a multicentre study 171
Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis 169
2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus 169
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 158
Clinical and subclinical atherosclerosis in patients with systemic sclerosis: an observational, multicentre study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 144
ASSESSING PRO-INFLAMMATORY PROPERTIES OF H-FERRITIN BY EX VIVO AND IN VITRO OBSERVATIONS 127
Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study 125
The clinical assessment of lung involvement in patients with Still’s disease, results from the multicentre international AIDA Network Still’s Disease Registry 123
The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmod 122
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 121
Association Between Minor Salivary Gland Biopsy During Sjӧgren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis 121
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 120
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 118
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment 118
Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study 118
). IL-6 e TGF-b1 nel siero e nei sovranatanti di cellule mononucleate in pazienti con sclerosi sistemica (SSC). 114
Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with Sjogren’s syndrome 112
Recent advances and evolving concepts in Still's disease 111
Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts 111
Activation antigens and adhesion molecules expression on Vd1+ T cells in systemic sclerosis (SSc) 109
Cytokine storm syndrome in severe COVID-19 109
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 108
Correction to: Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study 107
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease 106
Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data 106
EVIDENCE FOR REDUCED ANGIOGENESIS IN BONE MARROW (BM) IN SYSTEMIC SCLEROSIS (SSC) 105
Association between clinical, histopathological and molecular features in primary Sjogren's Syndrome: a retrospective study 105
Development and implementation of the AIDA International Registry for patients with Behçet's disease 104
The Relationship Between Metabolic Syndrome and Pain Catastrophizing in Psoriatic Arthritis 100
Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study 99
Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case–control study 99
How the different systemic organ involvements are overlapped in patients with primary Sjogren syndrome: analysis using a mathematical model 99
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 98
Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial 98
The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still's disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles 94
Polyclonal B lymphocyte activation in progressive systemic sclerosis. 92
Cardiovascular disease in primary sjögren’s syndrome 92
The Effect of Ketogenic Diet on Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review 92
Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort 91
SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients 91
The economic burden of fibromyalgia: A systematic literature review 90
Association between Patient Acceptable Symptom State and disease activity in psoriatic arthritis is disrupted by confounders, including comorbid fibromyalgia 89
Interstitial Lung Disease and Pulmonary Damage in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis 87
Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome 86
Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis 83
Clinical targeted treatment in Sjogren's disease: A systematic literature review for an evidence-based medicine approach 81
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 80
Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis 79
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 79
EULAR Textbook on Rheumatic Diseases – Third Edition (2018) 78
Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study 77
Correction: Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry 76
Primary versus systemic-sclerosis-associated Raynaud's phenomenon: relationship with clinical and environmental factors 76
Association Between the Use of Oral Contraceptives and the Development of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis 75
The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis 75
Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases 74
The Vessels Contribute to Fibrosis in Systemic Sclerosis 74
SCLERODERMA FIBROBLASTS SUPPRESS ANGIOGENESIS VIA TGF-beta/CAVEOLIN-DEPENDENT SECRETION OF PIGMENTED EPITHELIUM DERIVED FACTOR: TGF-beta RECEPTOR INHIBITORS AS A NOVEL THERAPEUTIC TARGET FOR THE TREATMENT OF SCLERODERMA 74
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome 74
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 73
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients 72
Vascular complications of scleroderma 72
The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort 71
The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational “real-life” study 70
Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjögren's Syndrome 70
Beyond the joints, the extra-articular manifestations in rheumatoid arthritis 70
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis 70
New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function 69
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? 69
Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjögren's Syndrome 69
Systemic Sjogren presenting without sicca syndrome: characterization of 240 patients according to the new 2017 ACR/EULAR Classification Criteria 68
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 68
Interstitial lung disease in systemic sclerosis: Pathophysiology and therapy 67
Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications 66
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 66
Co-Occurrence of Anti-Synthetase Syndrome and Sjögren Disease: A Case-Based Review 65
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 65
The kaleidoscope of neurological manifestations in primary Sjögren's syndrome 65
Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications 65
Totale 11.805
Categoria #
all - tutte 249.370
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 249.370


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022648 0 5 29 4 7 2 4 4 55 29 19 490
2022/2023318 5 15 11 28 73 13 6 7 10 11 130 9
2023/20241.786 60 216 61 144 198 839 32 85 17 51 40 43
2024/202510.867 230 179 617 113 109 364 242 64 1.422 1.088 3.012 3.427
2025/202616.151 1.556 496 1.216 2.243 456 944 4.069 1.311 1.231 1.258 801 570
2026/20271.577 183 1.394 0 0 0 0 0 0 0 0 0 0
Totale 31.347